Merrimack to present Pre-Clinical Data on MM-121 and MM-111 at the AACR Annual Meeting This Week

Pre-clinical data on MM-121 with selected cancer therapies and their combined effect in different cancer models, also in combination with targeted cancer therapies. Pre-clinical data on MM-111 as a montherapy to treat tumors overexpressing ErbB2.
Spread the Word
Listed Under

American Association For Cancer Research
Systems Biology
Network Biology
Modeling Erbb

• Cancer

New London - Connecticut - US

April 16, 2009 - PRLog -- Cambridge, MA -- Merrimack Pharmaceuticals, Inc., announced today that it will present pre-clinical data on MM-121 and MM-111, the two lead candidates in the company's pipeline of five novel cancer antibodies, at the Annual Meeting of the American Association for Cancer Research being held April 18-22, 2009, in Denver, CO.

Posters  1243 and 3244 will show pre-clinical data on MM-121, a monoclonal antibody designed to block signaling of the ErbB3 receptor. The ErbB3 receptor family has been known for years to have an impact on cancer signaling, but in 2003, Merrimack gained insight into the critical role of the ErbB3 receptor in cancer biology through the use of their core technology, the Network Biology platform, that led to the novel design of MM-121.
Poster 1243 -- shows pre-clinical data on MM-121 with selected cancer therapies and their combined effect in different cancer models.
Poster 3244 -- shows the benefit of using the Network Biology approach to select synergistic drug combinations of MM-121 with targeted therapies to treat ErbB pathway-driven tumors in multiple cancer models.
In 2008, MM-121 became the first selective ErbB3 antagonist to enter human clinical development. Results of Phase I studies of MM-121 will be presented this fall.

Posters 5472 and 3298 will show pre-clinical data on MM-111, a bi-specific antibody that links ErbB2 and ErbB3 to stop the signaling between these two cell receptors to disable their impact on pAKT, which plays an important role in cancer cell survival.
Poster 5472 -- looks at MM-111 as a monotherapy to treat tumors overexpressing ErbB2 (HER2+).
Poster 3298 -- shows the discovery and development of MM-111 through the use of computational modeling of selected biological systems. Merrimack applies this systems biology driven approach to drug discovery thorugh the Network Biology platform.

About Merrimack
Merrimack Pharmaceuticals, Inc., is a biotechnology company focused on the discovery and development of novel treatments for cancer. The company's proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, enables the high-throughput profiling of protein networks as a basis for improved validation, lead identification and speed in the development of innovative, effective and well tolerated therapeutics. Merrimack is a privately-held company based in Cambridge, Massachusetts. For additional information, please visit

# # #

RaymondStevenson Healthcare Communications (RSHC) is a boutique public relations consulting firm supporting the pharmaceutical, biotechnology and public health sectors.
Source:Betsy Raymond Stevenson
Email:*** Email Verified
Tags:Merrimack, American Association For Cancer Research, Cancer, Antibodies, Systems Biology, Network Biology, Modeling Erbb
Industry:Medical, Research, Cancer
Location:New London - Connecticut - United States
Account Email Address Verified     Disclaimer     Report Abuse

Like PRLog?
Click to Share